Nyxoah S.A.

New CMS procedure codes set for 2026 are seen as a pivotal step toward reimbursement clarity for the Genio system. Analysts maintaining higher price targets argue this regulatory progress directly supports the company's long-term revenue ramp and removes a key overhang for institutional investors considering the stock.

Despite positive CMS code developments, analysts have repeatedly trimmed price targets — from €12 to €9 and from $18.60 to $13.00 — citing the still-demanding reimbursement approval process as a persistent headwind that continues to delay meaningful commercial adoption of the Genio system in the U.S. market.

U.S. net revenue grew 25% quarter over quarter, with early Genio launch metrics including 15 implants and 35 VAC approvals viewed as concrete execution milestones. Optimistic analysts argue that Q4 guidance of €3.4M–€3.6M is appropriately calibrated and that the commercial ramp is on track with expectations.

Technical indicators signal persistent selling pressure, and preliminary Q2 2026 revenue of €7.7M came in below the consensus expectation of €8.64M. Analysts at Stifel reiterated a Hold rating and cut their price target to $3, explicitly citing capital concerns and a slower-than-anticipated commercial ramp as key risks.

Insider purchases of over $6.3 million in June 2026 at $1.72 per share by Chairman Robert Taub and Independent Director Dr. Jürgen Hambrecht signal strong internal conviction in the company's prospects. Analysts forecasting 39% annual revenue growth argue the commercial trajectory justifies current capital deployment and long-term valuation.

Analysts flag that Nyxoah is forecast to remain unprofitable through 2028, with projected operating cash outflows of up to €72M annually. The stock's fair value estimate was cut from €5.00 to €4.00 following a capital raise, and Stifel's explicit mention of 'capital concerns' highlights fears that additional dilutive financing may be necessary.